Topics: News
Twenty paintings are available to the highest bidders in a unique art auction benefiting the Foundation for Prader-Willi Research (FPWR).
Join us September 30-October 1 for our annual gathering of movers, shakers, thinkers, and doers at this year’s FPWR Family Conference! Here are the top 10 reasons you need to be there:
Topics: News
You won’t want to miss these speakers at the 2022 FPWR Family Conference this September and October in Chicago, IL. Are you ready to join like-minded game-changers with direct access to the people, knowledge, and inspiration you need to help your chi...
Topics: News
Natalie is a veteran to our community of dedicated movers and shakers and has been involved with our Foundation since the birth of her son in 2015. We are excited to bring her onboard so she can put her talents and experience to use supporting other ...
Topics: News
The Foundation for Prader-Willi Research (FPWR), Foundation for Angelman Syndrome Therapeutics (FAST), Angelman Syndrome Foundation (ASF), and Dup15q Alliance announce a collaborative initiative to fund the addition of chromosome 15 conditions to Ear...
Would you like to be part of our community-wide effort to advocate for new treatments for PWS? The FDA is now accepting comments from the public regarding a new drug application currently under review for LV-101 (intranasal carbetocin), a potential t...
On June 17, 2021, FPWR and PWSA | USA engaged the FDA in a Patient-Led Listening Session to share our community’s experiences related to Prader-Willi syndrome (PWS). The purpose of this meeting was to promote dialogue between the FDA and members of t...
Topics: News
Radius Health announced today their plans for a Pivotal Study for RAD011 for the treatment of hyperphagia in Prader-Willi syndrome. The Phase 2/3 study, SCOUT (Synthetic Cannabidiol Oral Solution), will evaluate safety and tolerability in PWS and is ...
Topics: News
In support of our mission to advance the development of new treatments for Prader-Willi syndrome (PWS), FPWR announces our newest venture philanthropy investment in Aardvark Therapeutics.
Topics: News